Androgen Receptor Expression in Triple-Negative Breast Cancer

Main Article Content

Samane Jam
Alireza Abdollahi
Sanaz Zand
Zahra Khazaeipour
Ramesh Omranipour
Massoome Najafi

Keywords

Triple Negative breast cancer (TNBC), Androgen receptor (AR), Histopathological features

Abstract

Background: Triple-negative breast cancer (TNBC) accounts for 15 to 20% of all breast cancers. These patients do not benefit from hormone therapy and other targeted treatments of breast cancer. Recently, researchers proposed the use of androgen receptor (AR)-targeted therapies in this subset of patients. The rate of AR expression in TNBC patients varies from 0 to 53%. AR positivity is associated with a better outcome for breast cancer patients. The purpose of this study was to evaluate AR status in TNBC patients and its association with other demographic and pathologic features.
Methods: This cross-sectional study was conducted in the Cancer Institute of Iran, affiliated with Tehran University of Medical Sciences, in 2015. Archived formalin-fixed, paraffin-embedded breast tumor blocks were evaluated to determine the AR status of the tumors. Demographic and pathologic characteristics of the patients were retrieved from the department of pathology database. Data were analyzed with SPSS 18.0.
Results: Seventy-seven TNBC patients with the mean age of 45.3 ± 11.5 were assessed. Twenty-six patients (34%) showed AR expression, and 51 patients (56%) did not have AR expression. There was no significant correlation between AR status and age, tumor size, histopathologic type of tumor, or lymph node involvement. However, AR positivity had a statistically significant association with a lower tumor grade and lymphovascular invasion (P = 0.029 and P = 0.01, respectively).
Conclusion: TNBC patients with AR expression tend to have lower tumor grades and higher rates of lymphovascular invasion.

References

1. Worldwide cancer data: Global cancer statistics for the most common cancers. 2018.
2. Mashoori N, Zand S, Nazemian R, Kaviani A. Effect of the surgery type, mastectomy vs. breast conserving surgery, on outcomes of patients with locally advanced breast cancer receiving neoadjuvant therapy. Archives of Breast Cancer. 2017;4(4):129-35.
3. Vohra P, Buelow B, Chen YY, Serrano M, Vohra MS, et al. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study. Cancer Cytopathol. 2016;124(11):828-35.
4. Yao H, He G, Yan S, Chen C, Song L, et al. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget. 2017;8(1):1913-24.
5. Mina A, Yoder R, Sharma P. Targeting the androgen receptor in triple-negative breast cancer: current perspectives. Onco Targets Ther. 2017;10:4675-85.
6. Jhan J-R, Andrechek ER. Triple-negative breast cancer and the potential for targeted therapy. Pharmacogenomics. 2017;18(17):1595-609.
7. Gerratana L, Basile D, Buono G, De Placido S, Giuliano M, et al. Androgen receptor in triple negative breast cancer: a potential target for the targetless subtype. Cancer Treatment Reviews. 2018.
8. McNamara K, Yoda T, Takagi K, Miki Y, Suzuki T, et al. Androgen receptor in triple negative breast cancer. The Journal of steroid biochemistry and molecular biology. 2013;133:66-76.
9. Wong Y, Xie B. The role of androgens in mammary carcinogenesis. Italian journal of anatomy and embryology= Archivio italiano di anatomia ed embriologia. 2001;106(2 Suppl 1):111-25.
10. Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res. 2013;19(19):5505-12.
11. Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Research. 2014;16(1):R7.
12. Toth-Fejel S, Cheek J, Calhoun K, Muller P, Pommier RF. Estrogen and androgen receptors as comediators of breast cancer cell proliferation: providing a new therapeutic tool. Archives of Surgery. 2004;139(1):50-4.
13. Mohammadizadeh F, Sajadieh S, Sajjadieh H, Kasaei Z. Androgen receptor expression and its relationship with clinicopathological parameters in an Iranian population with invasive breast carcinoma. Advanced biomedical research. 2014;3.
14. Choi JE, Kang SH, Lee SJ, Bae YK. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Annals of surgical oncology. 2015;22(1):82-9.
15. Ghannam A, Galal S, Ellity M. Expression of androgen receptors in primary breast cancer. European Society for Medical Oncology; 2016.
16. Mrklić I, Pogorelić Z, Ćapkun V, Tomić S. Expression of androgen receptors in triple negative breast carcinomas. Acta histochemica. 2013;115(4):344-8.
17. Pistelli M, Caramanti M, Biscotti T, Santinelli A, Pagliacci A, et al. Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. Cancers. 2014;6(3):1351-62.
18. Abd-Elazeem MA, Abd-Elazeem MA. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression. Annals of diagnostic pathology. 2015;19(1):37-42.
19. Rakha EA, El‐Sayed ME, Green AR, Lee AH, Robertson JF, et al. Prognostic markers in triple‐negative breast cancer. Cancer. 2007;109(1):25-32.
20. Park S, Koo J, Park H, Kim J-H, Choi S-Y, et al. Expression of androgen receptors in primary breast cancer. Annals of oncology. 2009;21(3):488-92.
21. McGhan LJ, McCullough AE, Protheroe CA, Dueck AC, Lee JJ, et al. Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype. Annals of surgical oncology. 2014;21(2):361-7.

Most read articles by the same author(s)